Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Rhea-AI Summary

Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The company focuses on developing therapeutics targeting toxic soluble amyloid beta oligomers for treating Alzheimer's disease. The management will join a fireside chat scheduled for May 20, 2024, at 12:30 p.m. ET. The event will be available via a live webcast on the company's investor relations page, with an archive accessible for 90 days.

Positive

• Participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference increases visibility and engagement with potential investors.
• Focus on developing novel therapeutics for Alzheimer's disease, addressing a significant unmet medical need.

Negative

• No new financial data or clinical trial updates were provided in the announcement.
• The impact on the stock price is uncertain as the participation in a conference does not directly translate to immediate financial gains.

CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2^nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com 

Media: 
AcumenPR@westwicke.com 

 

FAQ

When is Acumen Pharmaceuticals participating in the H.C. Wainwright 2nd Annual BioConnect Investor Conference?

Acumen Pharmaceuticals will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024.

What time is the Acumen Pharmaceuticals fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference?

The fireside chat is scheduled for 12:30 p.m. ET on May 20, 2024.

How can I watch the Acumen Pharmaceuticals presentation at the H.C. Wainwright 2nd Annual BioConnect Investor Conference?

The live webcast can be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

What is the focus of Acumen Pharmaceuticals' therapeutic development?

Acumen Pharmaceuticals is developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease.

What stock symbol is associated with Acumen Pharmaceuticals?

The stock symbol for Acumen Pharmaceuticals is ABOS.